Treatment of penicillin susceptible Staphylococcus aureus bacteraemia with bensylpenicillin versus cloxacillin – a randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506860-15-00

Acronym

COMeBAC

Enrollment

420

Registered

2024-02-09

Start date

2024-06-11

Completion date

Unknown

Last updated

2024-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Staphylococcus aureus bacteraemia

Brief summary

Alive at day 90 without complications. Complications defined as; relapse within 90 days from finishing antibiotic treatment, Change or addition of antibiotic treatment due to adverse events or clinical failure.

Interventions

DRUGBensylpenicillin Meda 1 g respektive 3 g pulver till injektions/infusionsvätska

DRUGlösning

DRUGCloxacillin Navamedic 2 g pulver till injektions-/infusionsvätska

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Alive at day 90 without complications. Complications defined as; relapse within 90 days from finishing antibiotic treatment, Change or addition of antibiotic treatment due to adverse events or clinical failure.	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026